跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

G2295

Sigma-Aldrich

格列美脲

≥98% (HPLC), solid

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C24H34N4O5S
CAS号:
93479-97-1
分子量:
490.62
MDL號碼:
MFCD00878417
分類程式碼代碼:
12352200
PubChem物質ID:
24895093
NACRES:
NA.77

品質等級

100

化驗

≥98% (HPLC)

形狀

solid

顏色

white

mp

212.2-214.5 °C

溶解度

DMSO: >10 mg/mL

起源

Sanofi Aventis

儲存溫度

room temp

SMILES 字串

CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)C1=O

InChI

1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

InChI 密鑰

WIGIZIANZCJQQY-RUCARUNLSA-N

基因資訊

human ... ABCC8(6833) , KCNJ1(3758) , KCNJ11(3767)

正在寻找类似产品? 访问 产品对比指南

一般說明

格列美脲属于生物制药II类二代磺酰脲类药物。

應用

格列美脲已被用于：
  • 作为一种降糖药物用于测试其在人脐静脉细胞（HUVEC）中的抗糖尿病功能
  • 在乳腺癌MDA-MB-231细胞中作为磺酰脲类ATP敏感型钾通道（KATP）抑制剂
  • 在新生儿胰岛样细胞簇（NICC）的葡萄糖刺激胰岛素分泌（GSIS）测定中检测其对胰岛素分泌的影响

格列美脲目前用于治疗 2 型糖尿病。

生化／生理作用

格列美脲可通过刺激胰腺β细胞分泌胰岛素激素来降低血糖水平。它可与与β细胞相关的一种65-kD蛋白发生相互作用。
格列美脲是一种有效的心肌梗死 KATP 通道阻断剂，被吡那地尔激活，IC50 值为 6.8 nM。

特點和優勢

该化合物由Sanofi Aventis开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。

象形圖

Health hazard
GHS08

訊號詞

Warning

危險聲明

H361

危險分類

Repr. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)

从最新的版本中选择一种：

分析证书(COA)

Lot/Batch Number
075M4753V
013M4715V
101M4733V
050M47111
050M4711

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Li-Ping Wang et al.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 38(6), 2337-2347 (2016-05-21)
By inducing severe endothelial impairment, hypertension and diabetes are two leading causes of morbidity and mortality. Hypertensive patients with concomitant diabetes must take both antihypertensive and hypoglycaemic medications, for which there is a lack of experimental and clinical guidelines. This
A REVIEW ARTICLE ON GLIMEPERIDE: AN ORAL HYPOGLYCAEMIC DRUG
Tiwari A, et al.
International Journal of Advanced Research , 4, 920-927 (2016)
W Rathmann et al.
Diabetes, obesity & metabolism, 15(1), 55-61 (2012-08-07)
To investigate therapy persistence, frequency of hypoglycaemia and macrovascular outcomes among type 2 diabetes patients with dipeptidyl peptidase-4 (DPP-4) inhibitors (DPP-4) and sulphonylureas (SU). Data from 19,184 DPP-4 (mean age: 64 years; 56% males) and 31,110 SU users (69 years;
Lan Gao et al.
International journal of technology assessment in health care, 28(4), 436-444 (2012-09-26)
The aim of this study was to evaluate the long-term cost-utility of liraglutide versus glimepiride as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM), based on the results of clinical trial conducted in Asian population. The
William T Cefalu et al.
Lancet (London, England), 382(9896), 941-950 (2013-07-16)
Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycaemia in patients with type 2 diabetes by enhancing urinary glucose excretion. We compared the efficacy and safety of canagliflozin, an SGLT2 inhibitor, with glimepiride in patients with type 2 diabetes inadequately controlled with
查看所有相关文献

商品

Insulin Signaling and Energy Homeostasis

Glucose metabolism is regulated by the opposing actions of insulin and glucagon. Insulin is released from pancreatic ß cells in response to high blood glucose levels and regulates glucose metabolism through its actions on muscle, liver, and adipose tissue.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门